SCYNEXIS, Inc. (NASDAQ: SCYX) Stock Competitors & Peer Comparison
See SCYX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SCYX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SCYX | $5.23 | -2.97% | 32.9M | -1.53 | -$3.42 | N/A |
| RPRX | $61.41 | +0.92% | 27.2B | 11.70 | $5.25 | +1.50% |
| CORT | $113.35 | -0.47% | 12.3B | 323.86 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $68.17 | +0.71% | 6.1B | 486.93 | $0.14 | N/A |
| KNSA | $78.63 | +0.70% | 6B | 87.37 | $0.90 | N/A |
| PBH | $51.78 | -1.32% | 2.5B | 11.71 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $22.02 | -9.12% | 1.3B | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
SCYX vs RPRX Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while RPRX trades at $61.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas RPRX's P/E ratio is 11.70. In terms of profitability, SCYX's ROE is -0.21%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SCYX is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
SCYX vs CORT Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CORT trades at $113.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CORT's P/E ratio is 323.86. In terms of profitability, SCYX's ROE is -0.21%, compared to CORT's ROE of +0.08%. Regarding short-term risk, SCYX is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
SCYX vs WBA Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas WBA's P/E ratio is -1.64. In terms of profitability, SCYX's ROE is -0.21%, compared to WBA's ROE of -0.42%. Regarding short-term risk, SCYX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
SCYX vs LQDA Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while LQDA trades at $68.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas LQDA's P/E ratio is 486.93. In terms of profitability, SCYX's ROE is -0.21%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, SCYX is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
SCYX vs KNSA Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while KNSA trades at $78.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas KNSA's P/E ratio is 87.37. In terms of profitability, SCYX's ROE is -0.21%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, SCYX is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
SCYX vs PBH Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, PBH has a market cap of 2.5B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while PBH trades at $51.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas PBH's P/E ratio is 11.71. In terms of profitability, SCYX's ROE is -0.21%, compared to PBH's ROE of +0.09%. Regarding short-term risk, SCYX is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
SCYX vs HROWL Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas HROWL's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, SCYX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
SCYX vs HROWM Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas HROWM's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, SCYX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
SCYX vs LTGO Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while LTGO trades at $22.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas LTGO's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to LTGO's ROE of N/A. Regarding short-term risk, SCYX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check LTGO's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
SCYX vs HELP Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, HELP has a market cap of 728.9M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while HELP trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas HELP's P/E ratio is -2.82. In terms of profitability, SCYX's ROE is -0.21%, compared to HELP's ROE of -0.71%. Regarding short-term risk, SCYX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
SCYX vs SVA Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas SVA's P/E ratio is -5.68. In terms of profitability, SCYX's ROE is -0.21%, compared to SVA's ROE of -0.01%. Regarding short-term risk, SCYX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
SCYX vs CUVL Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CUVL has a market cap of 300M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CUVL trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CUVL's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to CUVL's ROE of N/A. Regarding short-term risk, SCYX is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
SCYX vs CELG-RI Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CELG-RI has a market cap of 244.9M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, SCYX is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
SCYX vs HITI Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, HITI has a market cap of 220.6M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while HITI trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas HITI's P/E ratio is -7.36. In terms of profitability, SCYX's ROE is -0.21%, compared to HITI's ROE of -0.43%. Regarding short-term risk, SCYX is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check HITI's competition here
Atlantic International Corp. (NASDAQ: ATLN)
SCYX vs ATLN Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas ATLN's P/E ratio is -0.68. In terms of profitability, SCYX's ROE is -0.21%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, SCYX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
SCYX vs CTOR Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CTOR has a market cap of 71.6M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CTOR trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CTOR's P/E ratio is -1.64. In terms of profitability, SCYX's ROE is -0.21%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, SCYX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check CTOR's competition here
Stablecoin Development Corp. (AMEX: SDEV)
SCYX vs SDEV Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, SDEV has a market cap of 47.3M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while SDEV trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas SDEV's P/E ratio is -0.16. In terms of profitability, SCYX's ROE is -0.21%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, SCYX is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
SCYX vs RAD Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas RAD's P/E ratio is -0.05. In terms of profitability, SCYX's ROE is -0.21%, compared to RAD's ROE of +2.76%. Regarding short-term risk, SCYX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check RAD's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
SCYX vs NSRX Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, NSRX has a market cap of 35.2M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while NSRX trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas NSRX's P/E ratio is -5.67. In terms of profitability, SCYX's ROE is -0.21%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, SCYX is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check NSRX's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
SCYX vs GLTO Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas GLTO's P/E ratio is -1.78. In terms of profitability, SCYX's ROE is -0.21%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, SCYX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check GLTO's competition here
Biofrontera Inc. (NASDAQ: BFRI)
SCYX vs BFRI Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, BFRI has a market cap of 19.6M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while BFRI trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas BFRI's P/E ratio is -2.78. In terms of profitability, SCYX's ROE is -0.21%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, SCYX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
SCYX vs CNSY Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CNSY has a market cap of 19.4M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CNSY trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CNSY's P/E ratio is -0.39. In terms of profitability, SCYX's ROE is -0.21%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, SCYX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
SCYX vs SCNX Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, SCNX has a market cap of 15.8M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while SCNX trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas SCNX's P/E ratio is -0.15. In terms of profitability, SCYX's ROE is -0.21%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, SCYX is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
SCYX vs BFRIW Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, BFRIW has a market cap of 14.7M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, SCYX's ROE is -0.21%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, SCYX is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
SCYX vs COSM Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, COSM has a market cap of 13.2M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while COSM trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas COSM's P/E ratio is -0.33. In terms of profitability, SCYX's ROE is -0.21%, compared to COSM's ROE of -1.19%. Regarding short-term risk, SCYX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check COSM's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
SCYX vs CJJD Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CJJD's P/E ratio is -0.46. In terms of profitability, SCYX's ROE is -0.21%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, SCYX is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
SCYX vs SSY Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas SSY's P/E ratio is -2.86. In terms of profitability, SCYX's ROE is -0.21%, compared to SSY's ROE of -0.09%. Regarding short-term risk, SCYX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
SCYX vs POM Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while POM trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas POM's P/E ratio is -0.19. In terms of profitability, SCYX's ROE is -0.21%, compared to POM's ROE of +0.16%. Regarding short-term risk, SCYX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
SCYX vs BGMS Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, BGMS has a market cap of 4.8M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while BGMS trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas BGMS's P/E ratio is -0.24. In terms of profitability, SCYX's ROE is -0.21%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, SCYX is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
SCYX vs PAVS Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, PAVS has a market cap of 4.5M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while PAVS trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas PAVS's P/E ratio is -0.06. In terms of profitability, SCYX's ROE is -0.21%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, SCYX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
SCYX vs MDVL Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas MDVL's P/E ratio is -0.05. In terms of profitability, SCYX's ROE is -0.21%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, SCYX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
SCYX vs ATNFW Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas ATNFW's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, SCYX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
SCYX vs BGMSP Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, SCYX's ROE is -0.21%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, SCYX is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
SCYX vs AZNH Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas AZNH's P/E ratio is 38.35. In terms of profitability, SCYX's ROE is -0.21%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, SCYX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
SCYX vs LFLYW Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, SCYX's ROE is -0.21%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, SCYX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
SCYX vs PRPH Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, PRPH has a market cap of 294.3K. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while PRPH trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas PRPH's P/E ratio is -0.01. In terms of profitability, SCYX's ROE is -0.21%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, SCYX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
SCYX vs CPD Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, CPD has a market cap of 0. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas CPD's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to CPD's ROE of N/A. Regarding short-term risk, SCYX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check CPD's competition here
POZEN Inc. (NASDAQ: POZN)
SCYX vs POZN Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, POZN has a market cap of 0. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas POZN's P/E ratio is N/A. In terms of profitability, SCYX's ROE is -0.21%, compared to POZN's ROE of +0.61%. Regarding short-term risk, SCYX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check POZN's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
SCYX vs ESRX Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas ESRX's P/E ratio is 10.69. In terms of profitability, SCYX's ROE is -0.21%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, SCYX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
SCYX vs OREX Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, OREX has a market cap of 0. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas OREX's P/E ratio is -0.14. In terms of profitability, SCYX's ROE is -0.21%, compared to OREX's ROE of -0.54%. Regarding short-term risk, SCYX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check OREX's competition here
Shire plc (NASDAQ: SHPG)
SCYX vs SHPG Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas SHPG's P/E ratio is 11.35. In terms of profitability, SCYX's ROE is -0.21%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, SCYX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for SCYX.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
SCYX vs IPXL Comparison September 2026
SCYNEXIS, Inc. (NASDAQ: SCYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCYX stands at 32.9M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, SCYX is priced at $5.23 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCYX currently has a P/E ratio of -1.53, whereas IPXL's P/E ratio is -10.11. In terms of profitability, SCYX's ROE is -0.21%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, SCYX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for SCYX.Check IPXL's competition here